Brea, CA, United States
Brea, CA, United States

Beckman Coulter Inc., is an American company that makes biomedical laboratory instruments. Founded by Caltech professor Arnold O. Beckman in 1935 as National Technical Laboratories to commercialize a pH meter that he had invented, the company eventually grew to employ over 10,000 people, with $2.4 billion in annual sales by 2004. Its current headquarters are in Brea, California. Wikipedia.


Time filter

Source Type

"Fast diagnosis and treatment are critical for patients who have become septic," said Mike Samoszuk, M.D., vice president and chief medical officer at Beckman Coulter Diagnostics. "Adding PCT to our chemistry menu offers a tool for managing bacterial infections and sepsis, which should, inform the course and prognosis of the disease and facilitate therapeutic decisions. This addition is a result of our commitment to providing disease-state-management solutions." This assay is the first homogenous PCT assay for use on current Beckman Coulter AU model chemistry analyzers eliminating the need for costly dedicated instrumentation. The assay features a latex-enhanced immunoturbidimetric methodology, which uses multiple monoclonal antibodies for enhanced assay sensitivity and specificity. The high-quality, fully automated PCT assay is available for use with Beckman Coulter AU analyzers, models 480, 680 and 5800. "Healthcare providers face challenges in timely diagnosis of bacterial infections and sepsis," said Jack Zakowski, PhD, FACB, director, scientific affairs at Beckman Coulter. "Our AU analyzers are known for high performance, speed and accuracy. Combining our chemistry systems with this PCT assay results in fast turnaround times, and enables rapid assessment of patients in these critical situations." Beckman Coulter has partnered with Diazyme Laboratories to distribute the PCT assay to ensure delivery of the broadest range of solutions for clinical laboratories. Diazyme Laboratories is a cGMP and ISO 13485 certified medical device manufacturer, utilizing proprietary enzyme and immunoassay technologies to develop diagnostic reagents in user-friendly formats. Beckman Coulter Diagnostics helps healthcare and laboratory professionals provide better patient care by delivering the accurate diagnostic information they need, when they need it. For over 80 years, Beckman Coulter has been the partner of choice for healthcare organizations. Our scalable instruments, comprehensive diagnostic tests and business management services are trusted by hospitals, laboratories and other critical care settings around the world. We share in our customers' mission toward continuous improvement and quality patient care because we believe when efficiency and clinical outcomes are improved, patients benefit and we can move healthcare forward for every person. Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/beckman-coulter-diagnostics-expands-chemistry-menu-to-include-fda-cleared-procalcitonin-pct-300477167.html


News Article | June 6, 2017
Site: www.prweb.com

As part of the Beckman Coulter Life Sciences Virtual Trade Show Virtual Event, the latest in analytical methods to measure AAV particles will be discussed in a new webinar. Several examples of AAV vectors analysis will be presented, showing that AUC could be implemented as a routine test to monitor AAV product quality and manufacturing consistency. As gene therapy approaches usually require large amounts of AAV vectors for clinical use, few manufacturing processes have been reported to provide high titer and potent quantities of products. The dose control of AAV vectors is commonly established on titration methods relying either on the quantitation of DNA or transgene expression following cell transduction. Different indirect methods can be used to establish the ratio between full and empty AAV particles. The quantification of full capsids is performed by using qPCR based technology. The total particles can be evaluated by an ELISA assay, spectrometric analysis, ion-exchange chromatography or SDS-PAGE. However, these methods have limitations and are not applicable to all serotypes without performing a new development. This webinar will explore those limitations, as well as methods to quantify simultaneously empty and full AAV particles as well as intermediate species containing fragmented or incomplete vector genome. The team at Beckman Coulter Life Sciences has arranged for Dr. Christine Le Bec, head of analytical development at Genethon, to be the speaker for this webinar. Prior to joining Genethon, Le Bec obtained her doctorate in bio-organic chemistry from the Pierre and Marie Curie University. She joined Genethon in 1997 and currently heads the analytical development department. She is responsible for developing bioassays and setting up advanced analytical tools used for characterization and in release, in-process testing of gene therapy products at early stage development. LabRoots will host the webinar June 28, 2017, beginning at 7:00 a.m. PDT, 10 a.m. EDT. To read more about this event or to register for free, click here. About Beckman Coulter Beckman Coulter serves customers in two segments: Diagnostics and Life Sciences. The company develops, manufactures, and markets products that simplify, automate, and innovate complex biomedical testing. More than 275,000 Beckman Coulter systems operate in both Diagnostics and Life Sciences laboratories on seven continents. Scientists use Beckman Coulter’s Life Science research instruments to study complex biological problems, including causes of disease and potential new therapies or drugs. About LabRoots LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.


"We look forward to collaborating with our colleagues and partners at AACC this year to further relationships and deepen understanding. We know that, as significant changes occur in the healthcare landscape, our clinical partners face a host of challenges that require new ways of thinking," said Arnd Kaldowski, president, Beckman Coulter Diagnostics and Group Executive Diagnostics for Danaher. "We believe that patient care begins with the clinical laboratory. Helping serve patients in the safest and most efficient manner is our job, and, in fact, it is our vision to advance healthcare for every person." At the heart of the Beckman Coulter Diagnostics Difference, are the company's comprehensive high-quality clinical diagnostics solutions—exemplified by several new products featured in the booth this year, including the: The launch of these new products further expands portfolio spanning multiple disciplines, further expands the clinical diagnostic solutions available to customers through Danaher Corporation's network of companies, which include Beckman Coulter, Cepheid, Leica Biosystems, Radiometer and SCIEX Diagnostics. The breadth of offerings extends from established to highly advanced diagnostic technologies for clinical and anatomic pathology laboratories and point-of-care testing. With a rich history and tradition of innovation, the diagnostic companies of Danaher remain committed to helping healthcare systems build comprehensive and efficient diagnostic services to meet the evolving demands of highly integrated and coordinated healthcare delivery models. Laboratorians and healthcare professionals can learn more about Beckman Coulter Diagnostics solutions by participating in the company-hosted educational programs and in-booth presentations listed below. Detailed information is available here. Tuesday, August 1, 1:00 to 2:00 pm Sepsis and the Hematology Laboratory In this session, the clinical and laboratory-related characteristics of sepsis are described, with special emphasis on hematologic manifestations of sepsis. Speaker: Mike Samoszuk, M.D., Beckman Coulter Wednesday, August 2, 10:30 am to 12:00 pm The ASSESS Trial: A Multi-instrument Evaluation of 13 Commercial Troponin Assays, Sample Analysis in a Common Cohort of Samples Moderator: Robert Christenson, Ph.D., University of Maryland School of Medicine Speakers: Allison Chambliss, Ph.D., Keck School of Medicine of University of Southern California; Paramjit Sandhu, M.D., MPH, Centers for Disease Control and Prevention; Alan Wu, Ph.D., University of California San Francisco General Hospital Procalcitonin and its Role as a Biomarker for the Management of Sepsis                  Sherry Faye, Ph.D.      Tuesday, August 1, 12:00 pm New Challenges for Microbiology Laboratories in Antibiotic Susceptibility Testing Barbara Zimmer, Ph.D.             Tuesday, August 1, 1:00 pm H&H Testing: The Rule of Three Is Still Relevant Ahmed Bentahar M.D., Ph.D. Tuesday, August 1, 2:00 pm High-sensitivity Cardiac Troponin: What Does It Mean for Your Laboratory, Your Clinicians and Your Patients? Peter Kavsak Ph.D., FCACB, FACB, FCCS                 Tuesday, August 1, 3:00 pm Leveraging Service and Care Through Real-time Analysis of Provider Relationships and Behavior   Connor Billing Thursday, August 3, 10:00 am 9:30 am to 5:00 pm │ Tuesday, August 1 or Wednesday, August 2 Authors will be available at posters from 12:30 to 1:30 pm for discussion with attendees. A Prospective Observational Study of the Clinical Decision Impact on the Prostate Health Index (phi) Test in a Urology Practice Setting (A-141) A Comparison of the New Beckman Coulter DxC 700 AU Clinical Chemistry System to the UniCel DxC 800 Synchron Clinical Systems (B-440) Characteristics of the New Beckman Coulter Access hsTnI Assay (TBD) Biomarker Changes in Adult Men with Low Testosterone (low-T) (A-172) Improvement to Workflow in Reagent Dispense System Design in the New Beckman Coulter DxM MicroScan WalkAway System (B-075) Multicenter Evaluation of Imipenem MIC Results for Gram Negative Bacilli Using MicroScan Dried Gram Negative MIC Panels (A-123) Easy as 1, 2, 3? Trimester-specific TSH Reference Intervals in a Well-Characterized Population Using the Beckman Coulter (3rd IS) Immunoassay (TBD) Early Development of DxONE Insights, a Tool to Enhance Data-Driven Decision Making to Improve Laboratory Efficiency (B-028) Beckman Coulter Diagnostics helps healthcare and laboratory professionals provide better patient care by delivering the accurate diagnostic information they need, when they need it. For more than 80 years, Beckman Coulter has been the partner of choice for healthcare organizations. Our scalable instruments, comprehensive diagnostic tests and business management services are trusted by hospitals, laboratories and other critical care settings around the world. We share in our customers' mission toward continuous improvement and quality patient care, because we believe when efficiency and clinical outcomes are improved, patients benefit, and we can move healthcare forward for every person. Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. *Pending 510(k) clearance by the United States Food and Drug Administration; not yet available for in vitro diagnostic use in the United States. **Under development. The performance characteristics of this product have not been established. ***Not yet available for in vitro diagnostic use. Pending achievement of CE compliance, Canadian Licensure and other regulatory registrations. REMISOL Advance is a trademark or registered trademark of Normand-Info SAS in the United States and other countries. Used under license. Cepheid and GeneXpert are trademarks of Cepheid in the United States and other countries.


Alunni-Fabbroni M.,Beckman Coulter | Sandri M.T.,Italian National Cancer Institute
Methods | Year: 2010

Circulating Tumour Cells (CTCs) can be released from the primary tumour into the bloodstream and may colonize distant organs giving rise to metastasis. The presence of CTCs in the blood has been documented more than a century ago, and in the meanwhile various methods have been described for their detection. Most of them require an initial enrichment step, since CTCs are a very rare event. The different technologies and also the differences among the screened populations make the clinical significance of CTCs detection difficult to interprete. Here we will review the different assays up to now available for CTC detection and analysis. Moreover, we will focus on the relevance of the clinical data, generated so far and based on the CTCs analysis. Since the vast majority of data have been produced in breast cancer patients, the review will focus especially on this malignancy. © 2010 Elsevier Inc. All rights reserved.


Grant
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: PEOPLE-2007-1-1-ITN | Award Amount: 6.21M | Year: 2009

Understanding and controlling of interfacial phenomena in multiphase fluid dynamics remains one of the main challenges at the crossroad of Mathematics, Physics, Chemistry and Engineering. Examples include film flows, spreading and dewetting of (complex) liquids including suspensions, polymer solutions, liquid crystals, colloids and biofluids. Such systems are central for technological advances in the chemical, pharmaceutical, environmental and food industries and are crucial for the development of Microfluidics and Nanostructuring. The level of detail required by multi-scale flows with interfacial phenomena renders full-scale analyses practically impossible. In fact, such approaches often fail to describe even the results of simple experiments. MULTIFLOW will develop low-dimensional models capable of describing complex interfacial flows coupling different time and length scales. Based on the nature of the dominant mechanism, the scientific program will examine three generic classes: from nano- to macroscale, these are dominated by surface forces, reaction-diffusion, and advection. They are also affected by phase transitions, capillarity, chemical reactions, complex rheology and self-structuring. The strength of the network is its integration of all scientific disciplines, technical skills and expertise necessary to support the multi-scale nature of the envisaged research topics. By fostering the mobility and interdisciplinarity of a strong group of early-stage researchers through a set of well-defined objectives and effective networking between different institutions, disciplines and industries, the ultimate goals of this network are: (i) to create a multi-disciplinary, highly innovative and intersectorial training pool in the field of multi-scale interfacial fluid dynamics; (ii) to generate new tools and techniques for the theoretical-numerical-experimental investigation of such flows, which will be made available to the wider European Community.


Grant
Agency: European Commission | Branch: FP7 | Program: CP | Phase: FoF.NMP.2010-3 | Award Amount: 7.04M | Year: 2010

IMPRESS targets the development of a technological injection moulding platform for serial production of plastic components incorporating micro or nano scale functional features. The platform will be based on the gathering of up to date and most advanced facilities based on three main modules, each of them being a tool box including several building blocks: - a tool manufacturing module involving different technologies of micro- nano direct manufacturing, from top-down to bottom-up such as self-assembling, - an injection moulding module including equipments fitted with up to date hardware to improve replication quality and capability, - an intelligence module dedicated to advanced process control and online metrology integration. Beside this large panel of facilities, three case studies have been selected (biology, health and energy), each of them requiring a specific and well defined surface micro-nano texturation. These case studies cover a very large range of nano-feature (from 100nm up to 1 m) and component size (from 1 cm2 up to 1000 cm2). They will serve to qualify the capabilities of the different building blocks and will allow (i) to select the most suitable building blocks as of application requirements (ii) to learn about the platform working and (iii) to anticipate the technological future of the platform. Finally, a technico-economic tool for decision making will be developed based on the IMPRESS case studies and thus to allow end-users to select the most appropriate configuration regarding the end product manufacturing requirements. Further to the IMPRESS case studies, the performances of the platform will be validated through a satellite group. IMPRESS technological platform will accelerate the production and the time to market of micro nano-scale functional feature on multi-component devices in order to obtain an important reduction of needed supply chain space, technological risk and manufacturing costs of next generation plastic part products.


Patent
Beckman Coulter | Date: 2016-03-23

A device coupling comprising:a female portion 220 of the device coupling having a recess 228;a shaft 218 having a tapered surface 214 formed at one end 216 of the shaft 218, the tapered surface 214 being insertable into the recess 228 of the female portion 220; anda screw 212 configured to pull the shaft 218 into the recess 228 of the female portion 220 and join the shaft 218 to the female portion 220.


Patent
Beckman Coulter | Date: 2011-05-05

A diagnostic instrument having a cellular analysis system capable of running standardized immune monitoring panels. The system could include an automated and integrated specimen sampling method through a continuous flow process. The instrument could include a probe washer station, scheduler, cassette autoloader, bar coding system, and/or containment area common interface. An improved optimization test is proposed for instrument and flow cytometer quality assurance. The proposed method analyzes population separation for measuring instrument performance and/or sample quality. Such a method may also use population separation for measuring sample and/or run quality.


Patent
Beckman Coulter | Date: 2015-08-26

A diagnostic instrument is disclosed. The diagnostic instrument may have a highly efficient probe washer station and/or may be able to sense whether there is a tube septum on a specimen tube to be sampled. The instrument may also be able to determine where the bottom of the tube is located. The probe washer station may have a flow of saline that is used to wash both the internal cavity and the external circumference of the probe.


Patent
Beckman Coulter | Date: 2011-05-05

A diagnostic instrument is disclosed. The diagnostic instrument may have a highly efficient probe washer station and/or may be able to sense whether there is a tube septum on a specimen tube to be sampled. The instrument may also be able to determine where the bottom of the tube is located. The probe washer station may have a flow of saline that is used to wash both the internal cavity and the external circumference of the probe.

Loading Beckman Coulter collaborators
Loading Beckman Coulter collaborators